- US12331069utility2025DOT1L Degraders and Uses Thereof0 cites
- US12325725utility2025Cyclin-dependent Kinase Degraders and Methods of Use0 cites
- US12318452utility2025Degraders of WEE1 Kinase0 cites
- US12297426utility2025DNA Damage Response Signature Guided Rational Design of Crispr-based Systems and Therapies0 cites
- US12281126utility2025Inhibitors of Cyclin-dependent Kinase 7 and Uses Thereof0 cites
- US12268739utility2025Use of Toll-like Receptor 2 (TLR-2) Agonist for Modulating Human Immune Response0 cites
- US12268748utility2025Nucleic Acid Nanostructures Crosslinked with Oligolysine0 cites
- US12263166utility2025Methods of Treating Cancers Having a BRCA1 And/or BRCA2 Mutation(s)0 cites
- US12258560utility2025Compositions and Methods for Transient Gene Therapy with Enhanced Stability0 cites
- US12258323utility2025Dihydrooxadiazinones0 cites
- US12258378utility2025Engineered Cells, T Cell Immune Modulating Antibodies and Methods for Using the Same0 cites
- US12246004utility2025Therapeutic Treatment of Microsatellite Unstable Cancers0 cites
- USRE050319reissue2025Compounds and Methods for Treating Cancer0 cites
- US12239646utility2025Cancer Diagnostic and Treatment0 cites
- US12233128utility2025Degraders That Target ALK and Therapeutic Uses Thereof0 cites
- US12234220utility2025Immunomodulatory Compounds0 cites
- US12227488utility2025Small Molecule Degraders of Helios and Methods of Use0 cites
- US12227548utility2025Use of Ire1α-xbp1 Signaling Pathway Biomarkers for Modulating Immune Responses0 cites
- US12209076utility2025Imidazolyl Kinase Inhibitors and Uses Thereof0 cites